About WellChina

Who We Are

WellChina is an independent medical-tourism information platform for overseas patients researching healthcare in China. It is run by Shuangrui CHEN and a small professional team.

We publish in 8 languages — English, Simplified Chinese (overseas), Japanese, Korean, Russian, Indonesian, Vietnamese, and Thai — and currently cover 14+ JCI-accredited or international-friendly Chinese hospitals, 51 medical procedures across 10 categories, and price references benchmarked against 10 patient-origin countries.

We are not a hospital, not a clinic, not a doctor's practice, not a referral broker, not an insurance agency, and not a visa agency. We are an information layer — like a guidebook publisher — that helps patients form their own informed decisions before contacting hospitals directly.

Who We Serve — and Don't

We serve: foreign patients considering cross-border medical care in China — overseas Chinese, expatriates, medical-tourism shoppers from neighbouring countries, and English-speaking international patients.

We do not serve mainland Chinese residents. This is a deliberate scope decision rooted in regulatory boundaries (mainland Chinese medical-services advertising is regulated under different rules than international medical tourism), language localisation (our zh locale is targeted at overseas Simplified Chinese speakers, declared as zh-Hans-SG in our hreflang), and ethical positioning (mainland patients have direct, unmediated access to the same hospitals we describe; an English-language guidebook adds no value for them).

If you are a mainland Chinese resident, the platform will display a banner advising you to consult local sources. We do not capture or process inquiries from mainland IPs.

Our Mission

Make trustworthy, comparable medical-care information about China accessible to overseas patients in their native language, so that the cross-border decision is informed by facts the patient can verify — not by the cheapest middleman or the loudest hospital advertisement.

We believe the medical-tourism information gap costs patients money, time, and outcomes. Closing that gap, transparently, is the entire point of this platform.

What We Do

1. Map JCI-accredited or international-friendly Chinese hospitals — institutional data, specialty depth, English-language capability, accreditation status.
2. Benchmark prices against 10 patient-origin countries (US, UK, Germany, Japan, Korea, Russia, Indonesia, Vietnam, Thailand, India) with currency-converted, time-stamped, and source-attributed comparisons.
3. Verify English-speaking capability and international coordinator availability through direct contact with hospital intake departments.
4. Aggregate procedure information — costs, recovery, prerequisites, post-care — with citations back to authoritative sources (hospital websites, JCI registries, peer-reviewed journals, government health authorities).
5. Connect patients with hospital intake teams through our contact form, without commission, without markup, and without filtering of which hospitals patients choose.

What We Don't Do

• No medical advice. Diagnostic, treatment, and prognostic decisions are between you and a licensed physician — typically the treating hospital. We provide information that helps you ask better questions; we do not answer them.
• No commission from hospitals. We do not accept referral fees, finder's fees, or success-based payments from any healthcare provider. Our revenue comes from patient-side paid plans (described in Business Model).
• No advertising on the platform. No display ads, no sponsored hospital placements, no paid review boosts.
• No sale of visitor data. Inquiry data submitted through our forms is shared only with the hospital(s) the user explicitly selects, never with third-party marketers, data brokers, or insurance partners.
• No unreviewed medical content. Medical procedure descriptions follow our Editorial Policy — including a tiered review model that requires medical-reviewer sign-off before publication on YMYL (Your Money or Your Life) pages.

How We Add Value — 5 Pillars

We are an information intermediary, which means we do not produce original medical research. Our value lies in curation, verification, synthesis, and decision support — five concrete pillars:

1. Proprietary data. We maintain our own 10-country pricing reference table, currency-converted at controlled exchange rates with effective dates. This dataset does not exist elsewhere as a single comparable resource for overseas patients evaluating Chinese hospitals.

2. First-hand verification. JCI accreditation status, English-speaking capacity, international coordinator availability, and price effective dates are verified by direct contact with hospital intake departments — not scraped from third-party aggregators.

3. Synthesis. Hospitals appear in our directory only if they pass a triple filter: (a) JCI-accredited or equivalent international standard, (b) demonstrated English-language clinical capability, (c) named international patient coordinator. Most hospitals in China do not pass this filter; the curated subset is the value.

4. Decision support. Interactive tools — VisaFinder (medical-visa eligibility), price calculator, hospital comparison — convert raw information into actionable next steps for the patient's specific situation.

5. Transparency. Editorial Policy, Privacy Policy, this About page, and our Methodology page document how we research, review, source, and correct content. Every claim should be auditable; every disagreement has a documented corrections path.

Our Team

Principal Shuangrui CHEN. Background:

• MSc Machine Learning, University College London (Distinction)
• Dual BSc Mathematics + Computer Science, Université Paris-Saclay & Université Paris Cité (Très Bien, top 5%, French-language instruction)
• Senior machine-learning engineering roles at a major Chinese technology company, leading 21-person teams across multi-modal AI, agent platforms, and clinical AI workflow orchestration
• Clinical AI experience: led an end-to-end oncology pathology diagnostic AI pipeline (ViT + multiple-instance learning across 7+ cancer types and 30+ downstream tasks; VLLM-based pathology assistant integrated with hospital workflows) deployed across multiple hospitals
• Academic clinical research: research assistant at King's College London / Hypervision Surgical, applying invertible neural networks to hyperspectral-imaging estimation of tissue blood-perfusion physiology; validated on hypoxia experiments
• Bioinformatics & medical imaging agents on a multi-modal AI platform (RNA analysis, breeding analysis, medical-imaging diagnostic assistance) deployed in hospitals, labs, and enterprises

This medical-AI background informs how the platform structures hospital data, which AI tasks we trust to automation versus require human verification, and how we integrate editorial review into a content pipeline that uses AI as a drafting tool rather than a publishing tool.

Professional team. Editorial standards, source verification, and corrections handling are governed by our Editorial Policy.

Medical reviewers. Medical-reviewer onboarding is in progress per our public roadmap. Until at least one named medical reviewer is signed and visible in reviewedBy schema, all medical-procedure pages remain noindex as a defensive measure to avoid early misclassification by search engines and large-language-model crawlers.

Business Model

WellChina is self-funded and bootstrapped. We have no outside investors, no venture capital, and no corporate parent dictating roadmap or content priorities.

Revenue sources (current and planned):

• Patient-side paid subscription plans — concierge tier (translation support, document handling, in-China logistics) detailed on our Plans page. Users can use the entire information platform free of charge; paid tiers add hands-on assistance, not gated information.

What we do not monetise:

• We do not accept commission, referral fees, or success-based payments from hospitals or clinics.
• We do not sell, rent, or share visitor inquiry data with marketers, data brokers, or insurance partners.
• We do not display advertising on the platform.
• We do not accept payment for hospital placement, ranking elevation, review suppression, or content modification.

Why this funding model: any commission relationship between an information platform and the providers it describes structurally compromises editorial neutrality. A platform paid by hospitals will, over time, optimise for whatever hospitals will pay for — visibility, ranking, favourable language. We chose patient-side revenue precisely so that our incentive aligns with the patient's reading experience: more useful information, more honest verification, more transparent corrections.

If we ever revise this model — for example, introducing a hospital-side concierge service that involves payment flows — we will update this section before activating any such arrangement, and we will disclose it in Editorial Policy §conflict-of-interest.

How We Use AI

AI is a tool we use deliberately and disclose openly:

• Drafting. AI assists initial content generation for non-medical pages (city guides, visa overviews, payment overviews). Drafts are reviewed and edited by humans before publication.
• Translation. Our 7 non-English locales (Chinese, Japanese, Korean, Russian, Indonesian, Vietnamese, Thai) are produced via AI translation from the canonical English source. The English version is canonical for any factual disagreement.
• Verification. Hospital facts, prices, JCI status, and English-language capability are verified by humans, not AI — typically through direct hospital contact.
• Editorial review. Medical-content review and sign-off is performed by humans. AI drafts of medical content are not published without explicit medical-reviewer approval (see Editorial Policy).

Shuangrui CHEN's medical-AI background directly informs which categories of work we trust to automation (low-stakes drafting, translation) versus which require human judgment (medical-fact verification, editorial sign-off, conflict-of-interest review).

Trust & Compliance Links

• Editorial Policy — three-tier review model, source standards, corrections policy, conflict-of-interest commitments
• Privacy Policy — data handling, retention, and visitor rights
• Methodology — triple-filter hospital research, four-tier source classification, three-class verification cadence, AI/human boundary, pricing methodology with effective-from dates
• Contact — general inquiries

Last reviewed: 2026-04-26. Next scheduled review: 2027-04-26 or earlier if material changes occur.

Contact Us

• General inquiries: contact@wellchina.top
• Editorial corrections: file via Editorial Policy §corrections, or email contact@wellchina.top with subject line "Correction request"
• Press / partnerships / press inquiries: contact@wellchina.top

Response windows and corrections SLAs are documented in our Editorial Policy.